In Brief: Glaxo Wellcome top exec structure
Glaxo Wellcome top exec structure: Changed to aid the integration of the two companies and includes integration task forces and project teams. Chairing North American operations is Robert Ingram, Glaxo, Inc.'s CEO; Burroughs Wellcome North American Operations Director Phil Tracy to deputy chair; the R&D task force is led by Glaxo's Jim Niedel, MD; the deputy chair is Wellcome's David Barry, MD. Sir Richard Sykes, deputy chairman and CEO of Glaxo, plc, will take direct responsibility for public affairs and corporate strategy functions. Sykes will be the topsider at Glaxo Wellcome. Wellcome plc Chairman John Robb resigned, Wellcome announced March 23. His resignation is effective March 31...
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth